Rowook Park

Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.